GAL and neoplasm: Phase I clinical trials with such autologous tumorα-gal vaccines were performed by overnight incubation of α-gal presenting tumor cell membranes or intact cells with autologous anti-Gal and dendritic cells for enabling uptake of anti-Gal immunocomplexed tumor cell membranes by these APCs.